Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Ahead of print

Issues

Stability of tubular damage markers epidermal growth factor and heparin-binding EGF-like growth factor in urine

Laura R. Harskamp
  • Corresponding author
  • Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Esther Meijer
  • Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Harry van Goor
  • Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gerwin E. EngelsORCID iD: https://orcid.org/0000-0002-2520-3942 / Ron T. Gansevoort
  • Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-03-05 | DOI: https://doi.org/10.1515/cclm-2019-0152

References

  • 1.

    Bhavsar NA, Köttgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2012;60:233–40.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 2.

    Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012;156:785–95.Web of SciencePubMedCrossrefGoogle Scholar

  • 3.

    Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PX, et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015;7:316ra193.PubMedWeb of ScienceGoogle Scholar

  • 4.

    Harskamp LR, Gansevoort RT, van Goor H, Meijer E. The epidermal growth factor receptor pathway in chronic kidney diseases. Nat Rev Nephrol 2016;12:496–506.Web of ScienceCrossrefPubMedGoogle Scholar

  • 5.

    Betz B, Jenks SJ, Cronshaw AD, Lamont DJ, Cairns C, Manning JR, et al. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. Kidn Int 2016;89:1125–35.CrossrefGoogle Scholar

  • 6.

    Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. J Am Med Assoc 2011;305:1545–52.CrossrefWeb of ScienceGoogle Scholar

  • 7.

    Brinkman JW, de Zeeuw D, Gansevoort RT, Duker JJ, Kema IP, de Jong PE, et al. Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. Clin Chem 2007;53:153–4.PubMedWeb of ScienceGoogle Scholar

  • 8.

    Giesen C, Lieske JC. The influence of processing and storage conditions on renal protein biomarkers. Clin J Am Soc Nephrol 2016;11:1726–8.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 9.

    Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, et al. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol 2015;16:190.Web of ScienceCrossrefPubMedGoogle Scholar

  • 10.

    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, et al. Urinary EGF receptor ligand excretion in patients with autosomal dominant polycystic kidney disease and response to tolvaptan. Clin J Am Soc Nephrol 2015;10:1749–56.PubMedCrossrefWeb of ScienceGoogle Scholar

About the article

Corresponding author: Laura R. Harskamp, MD, Department of Nephrology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands, Phone: +31 50 361 6161, Fax: +31 50 361 9310


Received: 2019-02-08

Accepted: 2019-02-11

Published Online: 2019-03-05


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), 20190152, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2019-0152.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in